Emcure and Roche join forces to expand kidney and transplant drug access in India
Emcure and Roche join forces to expand kidney and transplant drug access in India
Emcure and Roche join forces to expand kidney and transplant drug access in India
Emcure Pharmaceuticals has partnered with Roche to distribute key nephrology and transplant medicines across India. The agreement, set to begin on 1 April 2026, will expand access to treatments for chronic kidney disease, anemia symptoms, and organ transplants. Both companies aim to improve patient care through wider availability of these specialised drugs.
Under the deal, Emcure will market and distribute Roche's established brands in India. These include CellCept, an immunosuppressant used in organ transplants, as well as Mircera and Neorecormon, which treat anemia in patients with chronic kidney disease. Mircera, a long-acting erythropoiesis-stimulating agent (ESA), requires dosing only once every two to four weeks.
Rajji Mehdwan, Managing Director and CEO of Roche India & Neighbouring Markets, highlighted Emcure's strong distribution network and clinical engagement. She noted that these strengths would help ensure the medicines reach more patients in need. Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, added that the partnership aligns with his company's focus on improving outcomes in anemia and renal care.
The collaboration will cover nationwide distribution, though no public data exists on how many doctors or clinics currently use Roche's nephrology and transplantation medicines in India.
The agreement will take effect from 1 April 2026, marking a step toward broader access to critical treatments. Patients with chronic kidney disease, anemia symptoms, and transplant needs may benefit from improved availability of Roche's specialised drugs. The partnership combines Emcure's distribution reach with Roche's established therapies in these areas.
B.C. expands deer hunt to combat chronic wasting disease outbreak
A deadly outbreak pushes B.C. to act—hunters get extra permits to thin deer herds. Can this stop the disease from spreading further?
India's fast-food boom clashes with rising obesity and diabetes crises
Urban lifestyles drive record fast-food demand, but the cost is steep: one in four adults now battles heart disease. Will stricter rules turn the tide?
SHIP study launches new health exams for 1,000 long-term participants
Decades of health insights unfold as SHIP's latest phase dives into ageing and disease. How will this data reshape public health research?
Silicosis Crisis Hits US Stone Workers as Industry Seeks Legal Shield
A grandfather and son both stricken by silicosis expose the hidden toll of quartz countertops. Now, the $30B industry wants Congress to block lawsuits—leaving families fighting for justice.